Drug Patents owned by Clovis Oncology Inc

1. Drug name - RUBRACA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6495541 CLOVIS ONCOLOGY INC Tricyclic inhibitors of poly(ADP-ribose) polymerases
Nov, 2023

(1 year, 1 month from now)

US8754072 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(8 years from now)

US9045487 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(8 years from now)

CN1342161A CLOVIS ONCOLOGY INC Poly (Adp-Ribose) Polymerase Of Tricyclic Inhibitors
Jan, 2020

(2 years ago)

CN100418967C CLOVIS ONCOLOGY INC Poly (Adp-Ribose) Polymerase Of Tricyclic Inhibitors
Jan, 2020

(2 years ago)

CN102884066B CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino{5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

CN104876937B CLOVIS ONCOLOGY INC 8 - (4 - (-2-[(Methylamino) Methyl] Phenyl} -1, 3, 4, 5-Tetrahydro - -6H - Benzoxazepine [5, 4, 3-Cd] -6 - Ketone Of The Maleate Salt, Pharmaceutical Composition Thereof And Use Thereof
Feb, 2031

(8 years from now)

CN104876937A CLOVIS ONCOLOGY INC 8 - (4 - (-2-[(Methylamino) Methyl] Phenyl} -1, 3, 4, 5-Tetrahydro - -6H - Azepine [5, 4, 3-Cd] -6 - Ketone Maleate Salt, Pharmaceutical Composition Thereof And Use Thereof
Feb, 2031

(8 years from now)

CN102884066A CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino{5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

IN200100805P3 CLOVIS ONCOLOGY INC Tricyclic Inhibitors Of Poly [Adp-Ribose]Polymerases
Jan, 2020

(2 years ago)

IN200884B CLOVIS ONCOLOGY INC Tricyclic Inhibitors Of Poly [Adp-Ribose] Polymerases
Jan, 2020

(2 years ago)

EP1140936B1 CLOVIS ONCOLOGY INC Tricyclic Inhibitors Of Poly(Adp-Ribose) Polymerases
Jan, 2020

(2 years ago)

EP1140936A1 CLOVIS ONCOLOGY INC Tricyclic Inhibitors Of Poly(Adp-Ribose) Polymerases
Jan, 2020

(2 years ago)

EP3150610A1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP3150610B1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP2534153B1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP2534153A1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7531530 CLOVIS ONCOLOGY INC Therapeutic compounds Jul, 2024

(1 year, 9 months from now)

US7351701 CLOVIS ONCOLOGY INC Therapeutic compounds Jul, 2024

(1 year, 9 months from now)

US8071579 CLOVIS ONCOLOGY INC DNA damage repair inhibitors for the treatment of cancer Aug, 2027

(4 years from now)

US8143241 CLOVIS ONCOLOGY INC DNA damage repair inhibitors for treatment of cancer Aug, 2027

(4 years from now)

US9861638 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb, 2031

(8 years from now)

US10278974 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb, 2031

(8 years from now)

US8859562 CLOVIS ONCOLOGY INC Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug, 2031

(8 years from now)

US9987285 CLOVIS ONCOLOGY INC High dosage strength tablets of rucaparib Aug, 2035

(12 years from now)

US10130636 CLOVIS ONCOLOGY INC High dosage strength tablets of rucaparib Aug, 2035

(12 years from now)

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation; A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation; A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription
EQ 250MG BASE TABLET;ORAL Prescription
EQ 300MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.